$THC
TENET HEALTHCARE CORP Stock $thc

$thc Overview Financials Valuation SEC Filings Company Website

2012 Q4 Form 10-K Financial Statement

#000110465913014113 Filed on February 26, 2013

Income Statement

Concept	2012 Q4	2011 Q4	2010 Q4
Revenue	$2.331B	$2.172B	$2.111B
YoY Change	7.32%	2.89%	-6.63%
Cost Of Revenue	$388.0M	$381.0M	$394.0M
YoY Change	1.84%	-3.3%	0.0%
Gross Profit	$1.943B	$1.791B	$1.717B
YoY Change	8.49%	4.31%	-8.03%
Gross Profit Margin	83.35%	82.46%	81.34%
Selling, General & Admin	$1.091B	$1.014B	$967.0M
YoY Change	7.59%	4.86%	-17.35%
% of Gross Profit	56.15%	56.62%	56.32%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$116.0M	$100.0M	$101.0M
YoY Change	16.0%	-0.99%	6.32%
% of Gross Profit	5.97%	5.58%	5.88%
Operating Expenses	$1.723B	$1.603B	$1.537B
YoY Change	7.49%	4.29%	-11.87%
Operating Profit	$220.0M	$188.0M	$180.0M
YoY Change	17.02%	4.44%	46.34%
Interest Expense	-$110.0M	-$100.0M	-$101.0M
YoY Change	10.0%	-0.99%	-0.98%
% of Operating Profit	-50.0%	-53.19%	-56.11%
Other Income/Expense, Net
YoY Change
Pretax Income	$97.00M	-$62.00M	$62.00M
YoY Change	-256.45%	-200.0%	-663.64%
Income Tax	$35.00M	-$12.00M	$2.000M
% Of Pretax Income	36.08%		3.23%
Net Earnings	$49.00M	-$70.00M	$80.00M
YoY Change	-170.0%	-187.5%	220.0%
Net Earnings / Revenue	2.1%	-3.22%	3.79%
Basic Earnings Per Share
Diluted Earnings Per Share	$426.1K	-$647.5K	$569.4K
COMMON SHARES
Basic Shares Outstanding	106.5M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2012 Q4	2011 Q4	2010 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$364.0M	$113.0M	$406.0M
YoY Change	222.12%	-72.17%	-42.25%
Cash & Equivalents	$364.0M	$113.0M	$405.0M
Short-Term Investments			$1.000M
Other Short-Term Assets	$458.0M	$378.0M	$289.0M
YoY Change	21.16%	30.8%	-31.68%
Inventory	$153.0M	$161.0M	$156.0M
Prepaid Expenses	$76.00M	$73.00M	$70.00M
Receivables	$1.345B	$1.278B	$1.143B
Other Receivables	$7.000M	$7.000M	$22.00M
Total Short-Term Assets	$2.681B	$2.357B	$2.311B
YoY Change	13.75%	1.99%	-6.51%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.293B	$4.350B	$4.304B
YoY Change	-1.31%	1.07%	-0.21%
Goodwill	$916.0M	$736.0M	$652.0M
YoY Change	24.46%	12.88%	7.41%
Intangibles
YoY Change
Long-Term Investments	$22.00M	$23.00M	$27.00M
YoY Change	-4.35%	-14.81%	-85.16%
Other Assets	$342.0M	$374.0M	$627.0M
YoY Change	-8.56%	-40.35%
Total Long-Term Assets	$6.363B	$6.105B	$6.189B
YoY Change	4.23%	-1.36%	12.92%
TOTAL ASSETS
Total Short-Term Assets	$2.681B	$2.357B	$2.311B
Total Long-Term Assets	$6.363B	$6.105B	$6.189B
Total Assets	$9.044B	$8.462B	$8.500B
YoY Change	6.88%	-0.45%	6.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$722.0M	$760.0M	$720.0M
YoY Change	-5.0%	5.56%	-2.57%
Accrued Expenses	$540.0M	$552.0M	$486.0M
YoY Change	-2.17%	13.58%	-15.18%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$94.00M	$66.00M	$67.00M
YoY Change	42.42%	-1.49%	3250.0%
Total Short-Term Liabilities	$1.763B	$1.815B	$1.725B
YoY Change	-2.87%	5.22%	-3.25%
LONG-TERM LIABILITIES
Long-Term Debt	$5.158B	$4.294B	$3.997B
YoY Change	20.12%	7.43%	-6.44%
Other Long-Term Liabilities	$305.0M	$506.0M	$554.0M
YoY Change	-39.72%	-8.66%	-47.39%
Total Long-Term Liabilities	$305.0M	$506.0M	$554.0M
YoY Change	-39.72%	-8.66%	-89.6%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.763B	$1.815B	$1.725B
Total Long-Term Liabilities	$305.0M	$506.0M	$554.0M
Total Liabilities	$7.810B	$6.954B	$6.681B
YoY Change	12.31%	4.09%	-8.57%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.288B	-$1.440B	-$1.522B
YoY Change	-10.56%	-5.39%
Common Stock	$7.000M	$7.000M	$27.00M
YoY Change	0.0%	-74.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.979B	$1.853B	$1.479B
YoY Change	6.8%	25.29%
Treasury Stock Shares	37.73M shares	34.11M shares	65.10M shares
Shareholders Equity	$1.143B	$1.423B	$1.766B
YoY Change
Total Liabilities & Shareholders Equity	$9.044B	$8.462B	$8.500B
YoY Change	6.88%	-0.45%	6.88%

Cashflow Statement

Concept	2012 Q4	2011 Q4	2010 Q4
OPERATING ACTIVITIES
Net Income	$49.00M	-$70.00M	$80.00M
YoY Change	-170.0%	-187.5%	220.0%
Depreciation, Depletion And Amortization	$116.0M	$100.0M	$101.0M
YoY Change	16.0%	-0.99%	6.32%
Cash From Operating Activities	$256.0M	$173.0M	$175.0M
YoY Change	47.98%	-1.14%	24.11%
INVESTING ACTIVITIES
Capital Expenditures	-$148.0M	-$173.0M	-$196.0M
YoY Change	-14.45%	-11.73%	2.08%
Acquisitions
YoY Change
Other Investing Activities	-$168.0M	-$6.000M	$47.00M
YoY Change	2700.0%	-112.77%	291.67%
Cash From Investing Activities	-$316.0M	-$179.0M	-$149.0M
YoY Change	76.54%	20.13%	-17.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$100.0M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	341.0M	-66.00M	-19.00M
YoY Change	-616.67%	247.37%	850.0%
NET CHANGE
Cash From Operating Activities	256.0M	173.0M	175.0M
Cash From Investing Activities	-316.0M	-179.0M	-149.0M
Cash From Financing Activities	341.0M	-66.00M	-19.00M
Net Change In Cash	281.0M	-72.00M	7.000M
YoY Change	-490.28%	-1128.57%	-117.07%
FREE CASH FLOW
Cash From Operating Activities	$256.0M	$173.0M	$175.0M
Capital Expenditures	-$148.0M	-$173.0M	-$196.0M
Free Cash Flow	$404.0M	$346.0M	$371.0M
YoY Change	16.76%	-6.74%	11.41%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-16000000	USD
CY2010	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-952000000	USD
CY2011	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	30000000	USD
CY2010	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	31000000	USD
CY2011	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-41000000	USD
CY2010	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	10000000	USD
CY2011	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	13000000	USD
CY2010	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	5000000	USD
CY2011	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	850000000	USD
CY2010	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	731000000	USD
CY2011	thc	Increase Decrease In Inventories And Other Assets Current IncreaseDecreaseInInventoriesAndOtherAssetsCurrent	35000000	USD
CY2011	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-5000000	USD
CY2011	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	63000000	USD
CY2010	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-3000000	USD
CY2011	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-32000000	USD
CY2011	thc	Payments For Restructuring And Litigation Costs PaymentsForRestructuringAndLitigationCosts	44000000	USD
CY2010	thc	Payments For Restructuring And Litigation Costs PaymentsForRestructuringAndLitigationCosts	83000000	USD
CY2011	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-38000000	USD
CY2010	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	472000000	USD
CY2011	thc	Payments To Acquire Property Plant And Equipment For Continuing Operations PaymentsToAcquirePropertyPlantAndEquipmentForContinuingOperations	467000000	USD
CY2012Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	1327000	shares
CY2012	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	19.75
CY2012Q4	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	470000000	USD
CY2012Q4	thc	Cash And Cash Equivalents Related To Captive Insurance Subsidiaries CashAndCashEquivalentsRelatedToCaptiveInsuranceSubsidiaries	65000000	USD
CY2011Q4	thc	Cash And Cash Equivalents Related To Captive Insurance Subsidiaries CashAndCashEquivalentsRelatedToCaptiveInsuranceSubsidiaries	92000000	USD
CY2012	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	98000000	USD
CY2012Q4	thc	Capital Expenditures Incurred But Not Yet Paid Current CapitalExpendituresIncurredButNotYetPaidCurrent	93000000	USD
CY2011Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1492000000	USD
CY2012	dei	Entity Registrant Name EntityRegistrantName	TENET HEALTHCARE CORP
CY2012	dei	Entity Central Index Key EntityCentralIndexKey	0000070318
CY2012	dei	Document Type DocumentType	10-K
CY2012	dei	Document Period End Date DocumentPeriodEndDate	2012-12-31
CY2012	dei	Amendment Flag AmendmentFlag	false
CY2012	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2012	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2012	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
CY2012	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8462000000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9044000000	USD
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1218000000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	1143000000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	7810000000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1763000000	USD
CY2012Q4	us-gaap	Assets Assets	9044000000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	2681000000	USD
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	401000000	USD
CY2011Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	397000000	USD
CY2011Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3386000000	USD
CY2011Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	360000000	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3494000000	USD
CY2012Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	426000000	USD
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.15
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.15
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000	shares
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000	shares
CY2012Q4	thc	Percentage Of Mandatory Convertible Shares PercentageOfMandatoryConvertibleShares	0.07	pure
CY2011Q4	thc	Percentage Of Mandatory Convertible Shares PercentageOfMandatoryConvertibleShares	0.07	pure
CY2012Q4	thc	Preferred Stock Seven Percent Mandatory Convertible Shares Issued PreferredStockSevenPercentMandatoryConvertibleSharesIssued	0	shares
CY2011Q4	thc	Preferred Stock Seven Percent Mandatory Convertible Shares Issued PreferredStockSevenPercentMandatoryConvertibleSharesIssued	345000	shares
CY2012Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	1000
CY2011Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	1000
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	262500000	shares
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	262500000	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	142363915	shares
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	137867138	shares
CY2012Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	37730431	shares
CY2011Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	34110674	shares
CY2011	thc	Health Care Organization Revenue Gross HealthCareOrganizationRevenueGross	9371000000	USD
CY2010	thc	Health Care Organization Revenue Gross HealthCareOrganizationRevenueGross	8992000000	USD
CY2011	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	717000000	USD
CY2010	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	727000000	USD
CY2011	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	8654000000	USD
CY2010	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	8265000000	USD
CY2011	us-gaap	Labor And Related Expense LaborAndRelatedExpense	4015000000	USD
CY2010	us-gaap	Labor And Related Expense LaborAndRelatedExpense	3830000000	USD
CY2011	us-gaap	Health Care Organization Medical Supplies And Drugs Expense HealthCareOrganizationMedicalSuppliesAndDrugsExpense	1548000000	USD
CY2010	us-gaap	Health Care Organization Medical Supplies And Drugs Expense HealthCareOrganizationMedicalSuppliesAndDrugsExpense	1542000000	USD
CY2011	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	2020000000	USD
CY2010	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	1857000000	USD
CY2011	thc	Electronic Health Record Incentives ElectronicHealthRecordIncentives	-55000000	USD
CY2011	us-gaap	Depreciation And Amortization DepreciationAndAmortization	398000000	USD
CY2010	us-gaap	Depreciation And Amortization DepreciationAndAmortization	380000000	USD
CY2011	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	20000000	USD
CY2010	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	10000000	USD
CY2010	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-12000000	USD
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	653000000	USD
CY2010	us-gaap	Operating Income Loss OperatingIncomeLoss	634000000	USD
CY2011	us-gaap	Interest Expense InterestExpense	375000000	USD
CY2010	us-gaap	Interest Expense InterestExpense	424000000	USD
CY2011	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-117000000	USD
CY2010	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-57000000	USD
CY2011	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	12000000	USD
CY2010	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	9000000	USD
CY2011Q4	thc	Physician Receivables And Relocation Agreements Current PhysicianReceivablesAndRelocationAgreementsCurrent	58000000	USD
CY2011	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	49000000	USD
CY2010	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1108000000	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	125000000	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	117000000	USD
CY2012	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-25000000	USD
CY2011	us-gaap	Gain Loss On Investments GainLossOnInvestments	3000000	USD
CY2010	us-gaap	Gain Loss On Investments GainLossOnInvestments	5000000	USD
CY2012	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-44000000	USD
CY2011	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	164000000	USD
CY2010	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	158000000	USD
CY2011	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	61000000	USD
CY2010	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-977000000	USD
CY2011	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	103000000	USD
CY2010	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	1135000000	USD
CY2011	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax	-18000000	USD
CY2010	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax	11000000	USD
CY2011	thc	Discontinued Operation Restructuring Settlement And Impairment Provisions Before Income Tax DiscontinuedOperationRestructuringSettlementAndImpairmentProvisionsBeforeIncomeTax	6000000	USD
CY2011	thc	Litigation And Investigation Costs LitigationAndInvestigationCosts	17000000	USD
CY2012	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	1000000	USD
CY2011	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	68000000	USD
CY2011	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	-32000000	USD
CY2010	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	-7000000	USD
CY2011	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-9000000	USD
CY2010	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	17000000	USD
CY2011	us-gaap	Profit Loss ProfitLoss	94000000	USD
CY2010	us-gaap	Profit Loss ProfitLoss	1152000000	USD
CY2011	us-gaap	Dividends Preferred Stock DividendsPreferredStock	24000000	USD
CY2010	us-gaap	Dividends Preferred Stock DividendsPreferredStock	24000000	USD
CY2011	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.09
CY2011	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.49
CY2011	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	58000000	USD
CY2010	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1119000000	USD
CY2010	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	1101000000	USD
CY2011	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-10000000	USD
CY2010	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	18000000	USD
CY2012	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.77
CY2012	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.42
CY2012	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.35
CY2012	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.70
CY2012	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.40
CY2012	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.30
CY2012	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	104200000	shares
CY2012	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	108926000	shares
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	141000000	USD
CY2012	us-gaap	Profit Loss ProfitLoss	133000000	USD
CY2012	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	209000000	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	749000000	USD
CY2012	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	9119000000	USD
CY2011	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax	15000000	USD
CY2010	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax	20000000	USD
CY2010	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	1000000	USD
CY2010	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeBeforeTax	1000000	USD
CY2011	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-15000000	USD
CY2010	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-18000000	USD
CY2011	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-6000000	USD
CY2010	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-7000000	USD
CY2011	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-9000000	USD
CY2010	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-11000000	USD
CY2011	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	85000000	USD
CY2010	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	1141000000	USD
CY2011	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	81000000	USD
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	24000000	USD
CY2010	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-3000000	USD
CY2010	thc	Increase Decrease In Inventories And Other Assets Current IncreaseDecreaseInInventoriesAndOtherAssetsCurrent	15000000	USD
CY2010	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-87000000	USD
CY2010	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-58000000	USD
CY2010	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	16000000	USD
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	497000000	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	320000000	USD
CY2010	thc	Construction Of New And Replacement Hospitals ConstructionOfNewAndReplacementHospitals	13000000	USD
CY2011	thc	Payments To Acquire Property Plant And Equipment For Discontinued Operations PaymentsToAcquirePropertyPlantAndEquipmentForDiscontinuedOperations	8000000	USD
CY2010	thc	Payments To Acquire Property Plant And Equipment For Discontinued Operations PaymentsToAcquirePropertyPlantAndEquipmentForDiscontinuedOperations	30000000	USD
CY2011	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	84000000	USD
CY2010	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	65000000	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-662000000	USD
CY2010	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	19000000	USD
CY2011	thc	Proceeds From Sale Of Marketable Securities Long Term Investments And Other Assets ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets	59000000	USD
CY2010	thc	Proceeds From Sale Of Marketable Securities Long Term Investments And Other Assets ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets	84000000	USD
CY2010	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-15000000	USD
CY2011	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	3000000	USD
CY2010	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-3000000	USD
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-503000000	USD
CY2010	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-420000000	USD
CY2011	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	365000000	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	593000000	USD
CY2011	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	445000000	USD
CY2011	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-292000000	USD
CY2011	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	843000000	USD
CY2010	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	886000000	USD
CY2011	us-gaap	Proceeds From Issuance Of Long Term Debt And Capital Securities Net ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet	900000000	USD
CY2010	us-gaap	Proceeds From Issuance Of Long Term Debt And Capital Securities Net ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet	601000000	USD
CY2011	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	21000000	USD
CY2010	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	27000000	USD
CY2011	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	374000000	USD
CY2010	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-285000000	USD
CY2011	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	24000000	USD
CY2010	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	24000000	USD
CY2011	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	10000000	USD
CY2010	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	8000000	USD
CY2011	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	6000000	USD
CY2010	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	7000000	USD
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-286000000	USD
CY2010	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-337000000	USD
CY2011	us-gaap	Interest Paid Net InterestPaidNet	-347000000	USD
CY2010	us-gaap	Interest Paid Net InterestPaidNet	-402000000	USD
CY2011	thc	Proceeds From Interest Rate Swap Agreement ProceedsFromInterestRateSwapAgreement	30000000	USD
CY2011	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-10000000	USD
CY2010	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	34000000	USD
CY2009Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	690000000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	405000000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	364000000	USD
CY2012Q2	thc	Preferred Stock Seven Percent Mandatory Convertible Shares Retired PreferredStockSevenPercentMandatoryConvertibleSharesRetired	298700	shares
CY2012Q2	dei	Entity Public Float EntityPublicFloat	1400757470	USD
CY2011Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1278000000	USD
CY2011Q4	us-gaap	Inventory Net InventoryNet	161000000	USD
CY2011Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	7000000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	418000000	USD
CY2011Q4	us-gaap	Assets Held For Sale Current AssetsHeldForSaleCurrent	2000000	USD
CY2011Q4	us-gaap	Other Assets Current OtherAssetsCurrent	378000000	USD
CY2012	us-gaap	Use Of Estimates UseOfEstimates	<div style='font-size:10.0pt;FONT-FAMILY: Times New Roman;'> <p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">Use of Estimates</font></i></b></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The preparation of financial statements, in conformity with accounting principles generally accepted in the United States of America (“GAAP”), requires us to make estimates and assumptions that affect the amounts reported in our Consolidated Financial Statements and these accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we base the estimates on historical experience and on assumptions that we believe to be reasonable given the particular circumstances in which we operate. Although we believe all adjustments considered necessary for a fair presentation have been included, actual results may vary from those estimates. Financial and statistical information we report to other regulatory agencies may be prepared on a basis other than GAAP or using different assumptions or reporting periods and, therefore, may vary from amounts presented herein. Although we make every effort to ensure that the information we report to those agencies is accurate, complete and consistent with applicable reporting guidelines, we cannot be responsible for the accuracy of the information they make available to the public.</font></p></div>
CY2012	us-gaap	Revenue Recognition Sales Of Services RevenueRecognitionSalesOfServices	<div style='font-size:10.0pt;FONT-FAMILY: Times New Roman;'> <p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">Net Operating Revenues Before Provision for Doubtful Accounts</font></i></b></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">We recognize net operating revenues before provision for doubtful accounts in the period in which our services are performed. Net operating revenues before provision for doubtful accounts primarily consist of net patient service revenues that are recorded based on established billing rates (i.e., gross charges), less estimated discounts for contractual and other allowances, principally for patients covered by Medicare, Medicaid, managed care and other health plans, as well as certain uninsured patients under our</font> <font style="FONT-SIZE: 10pt" size="2"><i>Compact with Uninsured Patients</i> (“Compact”).</font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Gross charges are retail charges. They are not the same as actual pricing, and they generally do not reflect what a hospital is ultimately paid and, therefore, are not displayed in our consolidated statements of operations. Hospitals are typically paid amounts that are negotiated with insurance companies or are set by the government. Gross charges are used to calculate Medicare outlier payments and to determine certain elements of payment under managed care contracts (such as stop-loss payments). Because Medicare requires that a hospital’s gross charges be the same for all patients (regardless of payer category), gross charges are also what hospitals charge all other patients prior to the application of discounts and allowances.</font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Revenues under the traditional fee-for-service Medicare and Medicaid programs are based primarily on prospective payment systems. Retrospectively determined cost-based revenues under these programs, which were more prevalent in earlier periods, and certain other payments, such as Indirect Medical Education, Direct Graduate Medical Education, disproportionate share hospital and bad debt expense, which are based on our hospitals’ cost reports, are estimated using historical trends and current factors. Cost report settlements under these programs are subject to audit by Medicare and Medicaid auditors and administrative and judicial review, and it can take several years until final settlement of such matters is determined and completely resolved. Because the laws, regulations, instructions and rule interpretations governing Medicare and Medicaid reimbursement are complex and change frequently, the estimates recorded by us could change by material amounts.</font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">We have a system and estimation process for recording Medicare net patient revenue and estimated cost report settlements. This results in us recording accruals to reflect the expected final settlements on our cost reports. For filed cost reports, we record the accrual based on those cost reports and subsequent activity, and record a valuation allowance against those cost reports based on historical settlement trends. The accrual for periods for which a cost report is yet to be filed is recorded based on estimates of what we expect to report on the filed cost reports, and a corresponding valuation allowance is recorded as previously described. Cost reports generally must be filed within five months after the end of the annual cost reporting period. After the cost report is filed, the accrual and corresponding valuation allowance may need to be adjusted. Adjustments for prior-year cost reports and related valuation allowances, principally related to Medicare and Medicaid, increased revenues in the years ended December 31, 2012, 2011 and 2010 by $114 million ($81 million related to the industry-wide Medicare Rural Floor Budget Neutrality Adjustment Settlement), $1 million and $1 million, respectively. Estimated cost report settlements and valuation allowances are deducted from accounts receivable in the accompanying Consolidated Balance Sheets (see Note 3). We believe that we have made adequate provision for any adjustments that may result from final determination of amounts earned under all the above arrangements with Medicare and Medicaid.</font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Revenues under managed care plans are based primarily on payment terms involving predetermined rates per diagnosis, per-diem rates, discounted fee-for-service rates and/or other similar contractual arrangements. These revenues are also subject to review and possible audit by the payers. The payers are billed for patient services on an individual patient basis. An individual patient’s bill is subject to adjustment on a patient-by-patient basis in the ordinary course of business by the payers following their review and adjudication of each particular bill. We estimate the discounts for contractual allowances at the individual hospital level utilizing billing data on an individual patient basis. At the end of each month, on an individual hospital basis, we estimate our expected reimbursement for patients of managed care plans based on the applicable contract terms. Contractual allowance estimates are periodically reviewed for accuracy by taking into consideration known contract terms as well as payment history. Although we do not separately accumulate and disclose the aggregate amount of adjustments to the estimated reimbursement for every patient bill, we believe our estimation and review process enables us to identify instances on a timely basis where such estimates need to be revised. We do not believe there were any adjustments to estimates of individual patient bills that were material to our revenues. In addition, on a corporate-wide basis, we do not record any general provision for adjustments to estimated contractual allowances for managed care plans. Managed care accounts, net of contractual allowances recorded, are further reduced to their net realizable value through provision for doubtful accounts based on historical collection trends for these payers and other factors that affect the estimation process.</font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">We know of no material claims, disputes or unsettled matters with any payer that would affect our revenues for which we have not adequately provided for in the accompanying Consolidated Financial Statements.</font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Under our Compact, the discount offered to uninsured patients is recognized as a contractual allowance, which reduces net operating revenues at the time the self-pay accounts are recorded. The uninsured patient accounts, net of contractual allowances recorded, are further reduced to their net realizable value through provision for doubtful accounts based on historical collection trends for self-pay accounts and other factors that affect the estimation process.</font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">We also provide charity care to patients who are financially unable to pay for the health care services they receive. Most patients who qualify for charity care are charged a per-diem amount for services received, subject to a cap. Except for the per-diem amounts, our policy is not to pursue collection of amounts determined to qualify as charity care; therefore, we do not report these amounts in net operating revenues or in provision for doubtful accounts. Patient advocates from Conifer’s Medical Eligibility Program screen patients in the hospital to determine whether those patients meet eligibility requirements for financial assistance programs. They also expedite the process of applying for these government programs.</font></p> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The table below shows the sources of net operating revenues before provision for doubtful accounts from continuing operations:</font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="55%"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="41%" colspan="8"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1">Years Ended December 31,</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="55%"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1">2012</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1">2011</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1">2010</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"> </font></b></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="55%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">General Hospitals:</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="55%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Medicare</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">$</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="10%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">2,195</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">$</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="10%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">2,068</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">$</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="10%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">2,050</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="55%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Medicaid</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">783</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">802</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">740</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="55%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Managed care</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">5,382</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">5,128</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">4,897</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="55%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Indemnity, self-pay and other</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">1,007</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">958</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">954</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="55%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Acute care hospitals — other revenue</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">69</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">105</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">115</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="55%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">Other:</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="55%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Other operations</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">468</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">310</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">236</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"> </font></p></td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="55%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">Net operating revenues before provision for doubtful accounts</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="2"> </font></b></p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">$</font></b></p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">9,904</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="2"> </font></b></p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">$</font></b></p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">9,371</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="2"> </font></b></p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">$</font></b></p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">8,992</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="2"> </font></b></p></td></tr></table></div>
CY2011	thc	Increase In Revenue Due To Adjustments For Prior Year Cost Reports And Related Valuation Allowances IncreaseInRevenueDueToAdjustmentsForPriorYearCostReportsAndRelatedValuationAllowances	1000000	USD
CY2010	thc	Increase In Revenue Due To Adjustments For Prior Year Cost Reports And Related Valuation Allowances IncreaseInRevenueDueToAdjustmentsForPriorYearCostReportsAndRelatedValuationAllowances	1000000	USD
CY2012	thc	Health Care Organization Revenue Gross HealthCareOrganizationRevenueGross	9904000000	USD
CY2012	thc	Provision For Doubtful Accounts Look Back Period ProvisionForDoubtfulAccountsLookBackPeriod	P18M
CY2012	thc	Percentage Of Medicaid Incentive Payments Federally Funded PercentageOfMedicaidIncentivePaymentsFederallyFunded	1.00	pure
CY2012	thc	Number Of Hospitals Operated By Subsidiaries NumberOfHospitalsOperatedBySubsidiaries	49	item
CY2012	thc	Number Of Licensed Beds In Hospitals Operated By Subsidiaries NumberOfLicensedBedsInHospitalsOperatedBySubsidiaries	13216	item
CY2012	thc	Cost Report Filing Period After End Of Annual Cost Reporting Period CostReportFilingPeriodAfterEndOfAnnualCostReportingPeriod	P5M
CY2012	thc	Increase In Revenue Due To Adjustments For Prior Year Cost Reports And Related Valuation Allowances IncreaseInRevenueDueToAdjustmentsForPriorYearCostReportsAndRelatedValuationAllowances	114000000	USD
CY2012	thc	Incentive Payments For Technology Certification IncentivePaymentsForTechnologyCertification	40000000	USD
CY2011	thc	Incentive Payments For Technology Certification IncentivePaymentsForTechnologyCertification	55000000	USD
CY2012Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	232000000	USD
CY2011Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	252000000	USD
CY2011	thc	Repatriated Cash From Subsidiaries RepatriatedCashFromSubsidiaries	21000000	USD
CY2011	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	109000000	USD
CY2011Q4	thc	Capital Expenditures Incurred But Not Yet Paid Current CapitalExpendituresIncurredButNotYetPaidCurrent	104000000	USD
CY2012	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	88000000	USD
CY2012	thc	Property Plant And Equipment Additions Minimum Value PropertyPlantAndEquipmentAdditionsMinimumValue	500	USD
CY2012	thc	Property Plant And Equipment Additions Minimum Useful Life PropertyPlantAndEquipmentAdditionsMinimumUsefulLife	P1Y
CY2012	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	6000000	USD
CY2011	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	8000000	USD
CY2010	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	4000000	USD
CY2011	us-gaap	Malpractice Loss Contingency Discount Rate MalpracticeLossContingencyDiscountRate	0.0135	pure
CY2012	us-gaap	Malpractice Loss Contingency Discount Rate MalpracticeLossContingencyDiscountRate	0.0118	pure
CY2011	thc	Percentage Of Net Operating Revenues Generated By General Hospitals PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals	0.967	pure
CY2012	thc	Percentage Of Net Operating Revenues Generated By General Hospitals PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals	0.953	pure
CY2010	thc	Percentage Of Net Operating Revenues Generated By General Hospitals PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals	0.974	pure
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2011Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	16000000	USD
CY2011Q4	us-gaap	Preferred Stock Value PreferredStockValue	334000000	USD
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	7000000	USD
CY2011Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4427000000	USD
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-52000000	USD
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1440000000	USD
CY2011Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1853000000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	1423000000	USD
CY2011Q4	us-gaap	Minority Interest MinorityInterest	69000000	USD
CY2012	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2012	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2011Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	64000000	USD
CY2011Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	362000000	USD
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1815000000	USD
CY2011Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	4294000000	USD
CY2011Q4	us-gaap	Self Insurance Reserve Noncurrent SelfInsuranceReserveNoncurrent	337000000	USD
CY2011Q4	us-gaap	Litigation Reserve Noncurrent LitigationReserveNoncurrent	2000000	USD
CY2011Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	506000000	USD
CY2011Q4	us-gaap	Liabilities Liabilities	6954000000	USD
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2010Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1819000000	USD
CY2009Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	697000000	USD
CY2012	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	12000000	USD
CY2011	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	10000000	USD
CY2010	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	8000000	USD
CY2010	us-gaap	Minority Interest Increase From Stock Issuance MinorityInterestIncreaseFromStockIssuance	1000000	USD
CY2012	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	37000000	USD
CY2011	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	14000000	USD
CY2012	us-gaap	Dividends Preferred Stock DividendsPreferredStock	11000000	USD
CY2012	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2011Q4	us-gaap	Assets Current AssetsCurrent	2357000000	USD
CY2011Q4	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	156000000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	374000000	USD
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4350000000	USD
CY2011Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	489000000	USD
CY2011Q4	us-gaap	Assets Assets	8462000000	USD
CY2011Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	66000000	USD
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	760000000	USD
CY2011Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	376000000	USD
CY2011Q4	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	75000000	USD
CY2011Q4	us-gaap	Interest Payable Current InterestPayableCurrent	112000000	USD
CY2012	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	126000000	USD
CY2011	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	374000000	USD
CY2012	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	10000000	USD
CY2011	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-18000000	USD
CY2010	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	12000000	USD
CY2012Q4	us-gaap	Stock Repurchase Program Authorized Amount StockRepurchaseProgramAuthorizedAmount	500000000	USD
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	18942000	shares
CY2012	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	20269000	shares
	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	19.75
CY2012Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	19.74
	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	26000000	USD
CY2012Q1	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	0	USD
CY2012	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	0	USD
CY2011Q4	us-gaap	Assets Held For Sale Long Lived AssetsHeldForSaleLongLived	20000000	USD
CY2010Q4	us-gaap	Assets Held For Sale Long Lived AssetsHeldForSaleLongLived	25000000	USD
CY2012	thc	Cash Payments To Be Applied Against Accruals Due Within One Year CashPaymentsToBeAppliedAgainstAccrualsDueWithinOneYear	7000000	USD
CY2012	thc	Cash Payments To Be Applied Against Accruals Due Thereafter CashPaymentsToBeAppliedAgainstAccrualsDueThereafter	5000000	USD
CY2012Q4	us-gaap	Restructuring Reserve RestructuringReserve	12000000	USD
CY2011Q4	us-gaap	Restructuring Reserve RestructuringReserve	11000000	USD
CY2012Q4	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	1095000	shares
CY2012Q4	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	2311000	shares
CY2012Q4	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	30.47
CY2012Q4	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	27.00
CY2012Q4	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	400000000	USD
CY2012Q4	thc	Common Stock Shares Authorized Before Reverse Stock Split CommonStockSharesAuthorizedBeforeReverseStockSplit	1050000000	shares
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1345000000	USD
CY2012	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	154000000	USD
CY2011	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	216000000	USD
CY2010	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	240000000	USD
CY2011	thc	Number Of Lawsuits NumberOfLawsuits	2	lawsuit
CY2011	thc	Litigation Settlements Net Of Insurance Recoveries LitigationSettlementsNetOfInsuranceRecoveries	14000000	USD
CY2011	us-gaap	Insurance Recoveries InsuranceRecoveries	10000000	USD
CY2010Q4	us-gaap	Litigation Reserve LitigationReserve	5000000	USD
CY2011	us-gaap	Loss Contingency Accrual Carrying Value Period Increase Decrease LossContingencyAccrualCarryingValuePeriodIncreaseDecrease	17000000	USD
CY2012	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	19000000	USD
CY2010Q4	us-gaap	Restructuring Reserve RestructuringReserve	10000000	USD
CY2009Q4	us-gaap	Restructuring Reserve RestructuringReserve	14000000	USD
CY2012	us-gaap	Restructuring Charges RestructuringCharges	-14000000	USD
CY2011	us-gaap	Restructuring Charges RestructuringCharges	-13000000	USD
CY2010	us-gaap	Restructuring Charges RestructuringCharges	-1000000	USD
CY2012	us-gaap	Restructuring Reserve Settled With Cash RestructuringReserveSettledWithCash	13000000	USD
CY2011	us-gaap	Restructuring Reserve Settled With Cash RestructuringReserveSettledWithCash	11000000	USD
CY2010	us-gaap	Restructuring Reserve Settled With Cash RestructuringReserveSettledWithCash	5000000	USD
CY2012	us-gaap	Restructuring Reserve Accrual Adjustment RestructuringReserveAccrualAdjustment	0	USD
CY2011	us-gaap	Restructuring Reserve Accrual Adjustment RestructuringReserveAccrualAdjustment	-1000000	USD
CY2010	us-gaap	Restructuring Reserve Accrual Adjustment RestructuringReserveAccrualAdjustment	0	USD
CY2012Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	119000000	USD
CY2011Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	32000000	USD
CY2012Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	116000000	USD
CY2011Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	129000000	USD
CY2012Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	5252000000	USD
CY2011Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	4360000000	USD
CY2012Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	94000000	USD
CY2012Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	5158000000	USD
CY2012Q4	us-gaap	Five Year Schedule Of Maturities Of Parent Company Repayments Of Principle Within One Year FiveYearScheduleOfMaturitiesOfParentCompanyRepaymentsOfPrincipleWithinOneYear	94000000	USD
CY2012Q4	us-gaap	Five Year Schedule Of Maturities Of Parent Company Repayments Of Principle In Year Two FiveYearScheduleOfMaturitiesOfParentCompanyRepaymentsOfPrincipleInYearTwo	104000000	USD
CY2012Q4	us-gaap	Five Year Schedule Of Maturities Of Parent Company Repayment Of Principle In Year Three FiveYearScheduleOfMaturitiesOfParentCompanyRepaymentOfPrincipleInYearThree	497000000	USD
CY2012Q4	us-gaap	Five Year Schedule Of Maturities Of Parent Company Repayments Of Principle In Year Four FiveYearScheduleOfMaturitiesOfParentCompanyRepaymentsOfPrincipleInYearFour	3000000	USD
CY2010	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	12000000	USD
CY2012Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	5368000000	USD
CY2012Q4	us-gaap	Five Year Schedule Of Maturities Of Parent Company Repayments Of Principle In Year Five FiveYearScheduleOfMaturitiesOfParentCompanyRepaymentsOfPrincipleInYearFive	3000000	USD
CY2012Q4	us-gaap	Five Year Schedule Of Maturities Of Parent Company Repayments Of Principal After Year Five FiveYearScheduleOfMaturitiesOfParentCompanyRepaymentsOfPrincipalAfterYearFive	4667000000	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	439000000	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	118000000	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	77000000	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	58000000	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	48000000	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	35000000	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	103000000	USD
CY2012	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	156000000	USD
CY2011	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	143000000	USD
CY2010	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	134000000	USD
CY2012	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	8000000	USD
CY2011	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	8000000	USD
CY2012	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	2000000	USD
CY2011Q4	us-gaap	Defined Benefit Plan Funded Status Of Plan DefinedBenefitPlanFundedStatusOfPlan	285000000	USD
CY2012Q4	thc	Common Stock Fair Value Per Share CommonStockFairValuePerShare	32.47
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4289192	shares
CY2012	thc	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Percentage Of Total ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentageOfTotal	1.000	pure
CY2012	thc	Defined Contribution Plan Employee Contribution Percentage Minimum DefinedContributionPlanEmployeeContributionPercentageMinimum	0.01	pure
CY2012	thc	Defined Contribution Plan Employee Contribution Percentage Maximum DefinedContributionPlanEmployeeContributionPercentageMaximum	0.75	pure
CY2012	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	32000000	USD
CY2011	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	32000000	USD
CY2010	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	26000000	USD
CY2012	thc	Defined Benefit Pension Plan Active Number DefinedBenefitPensionPlanActiveNumber	1	plan
CY2012	thc	Defined Benefit Pension Plan Frozen Number DefinedBenefitPensionPlanFrozenNumber	2	plan
CY2012	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	14000000	USD
CY2012	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	-30000000	USD
CY2012Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	-312000000	USD
CY2012Q4	us-gaap	Defined Benefit Plan Funded Status Of Plan DefinedBenefitPlanFundedStatusOfPlan	312000000	USD
CY2012	us-gaap	Defined Benefit Plan Benefits Paid DefinedBenefitPlanBenefitsPaid	-19000000	USD
CY2012Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	0	USD
CY2011Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	-285000000	USD
CY2011	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	2000000	USD
CY2011	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	14000000	USD
CY2011	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	-19000000	USD
CY2011	us-gaap	Defined Benefit Plan Benefits Paid DefinedBenefitPlanBenefitsPaid	-18000000	USD
CY2011Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	0	USD
CY2012Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	292000000	USD
CY2012Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax	90000000	USD
CY2012Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate	0.0400	pure
CY2011Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate	0.0500	pure
CY2012Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease	0.0300	pure
CY2011Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease	0.0300	pure
CY2012Q4	us-gaap	Defined Benefit Plan Accumulated Benefit Obligation DefinedBenefitPlanAccumulatedBenefitObligation	308000000	USD
CY2011Q4	us-gaap	Defined Benefit Plan Accumulated Benefit Obligation DefinedBenefitPlanAccumulatedBenefitObligation	280000000	USD
CY2012	us-gaap	Defined Benefit Plan Amortization Of Prior Service Cost Credit DefinedBenefitPlanAmortizationOfPriorServiceCostCredit	0	USD
CY2011	us-gaap	Defined Benefit Plan Amortization Of Prior Service Cost Credit DefinedBenefitPlanAmortizationOfPriorServiceCostCredit	0	USD
CY2010	us-gaap	Defined Benefit Plan Amortization Of Prior Service Cost Credit DefinedBenefitPlanAmortizationOfPriorServiceCostCredit	0	USD
CY2012	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-5000000	USD
CY2011	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-3000000	USD
CY2010	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-1000000	USD
CY2012	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	21000000	USD
CY2011	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	19000000	USD
CY2010	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	17000000	USD
CY2010	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	2000000	USD
CY2010	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	14000000	USD
CY2012	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate	0.0500	pure
CY2011	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate	0.0550	pure
CY2010	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate	0.0575	pure
CY2012	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease	0.0300	pure
CY2011	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease	0.0300	pure
CY2010	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease	0.0300	pure
CY2012Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Current Liabilities PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities	20000000	USD
CY2012Q4	us-gaap	Defined Benefit Plan Amounts Recognized In Balance Sheet DefinedBenefitPlanAmountsRecognizedInBalanceSheet	-222000000	USD
CY2011Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Current Liabilities PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities	20000000	USD
CY2011Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	265000000	USD
CY2011Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax	65000000	USD
CY2011Q4	us-gaap	Defined Benefit Plan Amounts Recognized In Balance Sheet DefinedBenefitPlanAmountsRecognizedInBalanceSheet	-220000000	USD
CY2012	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Net Unamortized Gain Loss Arising During Period Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax	-25000000	USD
CY2011	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Net Unamortized Gain Loss Arising During Period Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax	-16000000	USD
CY2010	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Net Unamortized Gain Loss Arising During Period Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax	-20000000	USD
CY2012	us-gaap	Other Comprehensive Income Reclassification Of Defined Benefit Plans Net Gain Loss Recognized In Net Periodic Benefit Cost Before Tax OtherComprehensiveIncomeReclassificationOfDefinedBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax	-30000000	USD
CY2011	us-gaap	Other Comprehensive Income Reclassification Of Defined Benefit Plans Net Gain Loss Recognized In Net Periodic Benefit Cost Before Tax OtherComprehensiveIncomeReclassificationOfDefinedBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax	-19000000	USD
CY2010	us-gaap	Other Comprehensive Income Reclassification Of Defined Benefit Plans Net Gain Loss Recognized In Net Periodic Benefit Cost Before Tax OtherComprehensiveIncomeReclassificationOfDefinedBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostBeforeTax	-21000000	USD
CY2012Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	-90000000	USD
CY2011Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	-65000000	USD
CY2010Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	-49000000	USD
CY2012Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	76000000	USD
CY2011Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	73000000	USD
CY2012Q4	thc	Physician Receivables And Relocation Agreements Current PhysicianReceivablesAndRelocationAgreementsCurrent	57000000	USD
CY2012Q4	thc	Physician And Group Coverage Guarantees Current PhysicianAndGroupCoverageGuaranteesCurrent	80000000	USD
CY2011Q4	thc	Physician And Group Coverage Guarantees Current PhysicianAndGroupCoverageGuaranteesCurrent	104000000	USD
CY2012Q4	thc	Disproportionate Share Hospital Revenue Receivables Current DisproportionateShareHospitalRevenueReceivablesCurrent	47000000	USD
CY2011Q4	thc	Disproportionate Share Hospital Revenue Receivables Current DisproportionateShareHospitalRevenueReceivablesCurrent	27000000	USD
CY2012Q4	us-gaap	Other Receivables OtherReceivables	74000000	USD
CY2011Q4	us-gaap	Other Receivables OtherReceivables	47000000	USD
CY2012Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	2000000	USD
CY2011Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	2000000	USD
CY2012Q4	thc	Electronic Health Record Incentives Receivable Current ElectronicHealthRecordIncentivesReceivableCurrent	8000000	USD
CY2011Q4	thc	Electronic Health Record Incentives Receivable Current ElectronicHealthRecordIncentivesReceivableCurrent	13000000	USD
CY2012Q4	thc	Supplemental California Medical Payment Receivable Current SupplementalCaliforniaMedicalPaymentReceivableCurrent	33000000	USD
CY2011Q4	thc	Supplemental California Medical Payment Receivable Current SupplementalCaliforniaMedicalPaymentReceivableCurrent	16000000	USD
CY2012Q4	thc	Sublease Receivables Current SubleaseReceivablesCurrent	1000000	USD
CY2011Q4	thc	Sublease Receivables Current SubleaseReceivablesCurrent	2000000	USD
CY2012Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	80000000	USD
CY2011Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	36000000	USD
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	458000000	USD
CY2012Q4	us-gaap	Financing Receivable Recorded Investment Equal To Greater Than90 Days Past Due FinancingReceivableRecordedInvestmentEqualToGreaterThan90DaysPastDue	53000000	USD
CY2011Q4	us-gaap	Financing Receivable Recorded Investment Equal To Greater Than90 Days Past Due FinancingReceivableRecordedInvestmentEqualToGreaterThan90DaysPastDue	38000000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7787000000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4293000000	USD
CY2012Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1076000000	USD
CY2011Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	849000000	USD
CY2012Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	15000000	USD
CY2012Q4	us-gaap	Equity Method Investments EquityMethodInvestments	22000000	USD
CY2012Q4	us-gaap	Long Term Investments LongTermInvestments	37000000	USD
CY2012Q4	us-gaap	Cash Surrender Value Of Life Insurance CashSurrenderValueOfLifeInsurance	21000000	USD
CY2012Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	16000000	USD
CY2012Q4	thc	Land Held For Expansion Long Term Receivables And Other Assets Noncurrent LandHeldForExpansionLongTermReceivablesAndOtherAssetsNoncurrent	88000000	USD
CY2012	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	8000000	USD
CY2011Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	22000000	USD
CY2012	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	117000000	USD
CY2011Q4	us-gaap	Equity Method Investments EquityMethodInvestments	23000000	USD
CY2011Q4	us-gaap	Long Term Investments LongTermInvestments	45000000	USD
CY2011Q4	us-gaap	Cash Surrender Value Of Life Insurance CashSurrenderValueOfLifeInsurance	18000000	USD
CY2011Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	47000000	USD
CY2011Q4	thc	Land Held For Expansion Long Term Receivables And Other Assets Noncurrent LandHeldForExpansionLongTermReceivablesAndOtherAssetsNoncurrent	46000000	USD
CY2012Q4	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	162000000	USD
CY2011	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	8000000	USD
CY2012Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	1000000	USD
CY2011Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	1000000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Cumulative Changes In Net Gain Loss From Cash Flow Hedges Effect Net Of Tax AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax	-1000000	USD
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Cumulative Changes In Net Gain Loss From Cash Flow Hedges Effect Net Of Tax AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax	-1000000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	67000000	USD
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	51000000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-68000000	USD
CY2012	us-gaap	Other Comprehensive Income Loss Reclassification Pension And Other Postretirement Benefit Plans Net Gain Loss Recognized In Net Periodic Benefit Cost Tax OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostTax	9000000	USD
CY2011	us-gaap	Other Comprehensive Income Loss Reclassification Pension And Other Postretirement Benefit Plans Net Gain Loss Recognized In Net Periodic Benefit Cost Tax OtherComprehensiveIncomeLossReclassificationPensionAndOtherPostretirementBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostTax	7000000	USD
CY2012	us-gaap	Malpractice Loss Contingency Claims Incurred Net MalpracticeLossContingencyClaimsIncurredNet	92000000	USD
CY2011	us-gaap	Malpractice Loss Contingency Claims Incurred Net MalpracticeLossContingencyClaimsIncurredNet	108000000	USD
CY2010	us-gaap	Malpractice Loss Contingency Claims Incurred Net MalpracticeLossContingencyClaimsIncurredNet	56000000	USD
CY2012Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	10000000	USD
CY2012	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-5000000	USD
CY2012	us-gaap	Loss Contingency Accrual Carrying Value Payments LossContingencyAccrualCarryingValuePayments	61000000	USD
CY2012	thc	Legal Costs And Transfers Other LegalCostsAndTransfersOther	0	USD
CY2011Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	66000000	USD
CY2011	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-55000000	USD
CY2011	us-gaap	Loss Contingency Accrual Carrying Value Payments LossContingencyAccrualCarryingValuePayments	36000000	USD
CY2011	thc	Legal Costs And Transfers Other LegalCostsAndTransfersOther	0	USD
CY2010Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	30000000	USD
CY2010	us-gaap	Loss Contingency Accrual Carrying Value Payments LossContingencyAccrualCarryingValuePayments	78000000	USD
CY2010	thc	Legal Costs And Transfers Other LegalCostsAndTransfersOther	1000000	USD
CY2009Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	95000000	USD
CY2012	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-3000000	USD
CY2011	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2010	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	6000000	USD
CY2012	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	11000000	USD
CY2011	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-6000000	USD
CY2010	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2012	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	8000000	USD
CY2011	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-6000000	USD
CY2010	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	6000000	USD
CY2012	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	117000000	USD
CY2011	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	62000000	USD
CY2010	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-929000000	USD
CY2011	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	5000000	USD
CY2010	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-54000000	USD
CY2012	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	117000000	USD
CY2011	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	67000000	USD
CY2010	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	-983000000	USD
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	125000000	USD
CY2011	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	57000000	USD
CY2011Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	418000000	USD
CY2010	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	55000000	USD
CY2012	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	13000000	USD
CY2011	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	10000000	USD
CY2012	us-gaap	Income Tax Reconciliation Minority Interest Income Expense IncomeTaxReconciliationMinorityInterestIncomeExpense	4000000	USD
CY2012	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-5000000	USD
CY2012	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-1000000	USD
CY2012	thc	Income Tax Reconciliation Prior Year Income Taxes And Change In Deferred Taxes IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes	-3000000	USD
CY2012	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	2000000	USD
CY2011	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	5000000	USD
CY2010	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	2000000	USD
CY2011	us-gaap	Income Tax Reconciliation Minority Interest Income Expense IncomeTaxReconciliationMinorityInterestIncomeExpense	4000000	USD
CY2010	us-gaap	Income Tax Reconciliation Minority Interest Income Expense IncomeTaxReconciliationMinorityInterestIncomeExpense	3000000	USD
CY2011	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-2000000	USD
CY2010	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1054000000	USD
CY2011	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-12000000	USD
CY2010	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	16000000	USD
CY2011	thc	Income Tax Reconciliation Prior Year Income Taxes And Change In Deferred Taxes IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes	-7000000	USD
CY2010	thc	Income Tax Reconciliation Prior Year Income Taxes And Change In Deferred Taxes IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes	3000000	USD
CY2010	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	10000000	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	375000000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Restructuring Charges DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges	5000000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Restructuring Charges DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges	5000000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	173000000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	178000000	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	53000000	USD
CY2011Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	53000000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Self Insurance DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance	182000000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Self Insurance DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance	197000000	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	122000000	USD
CY2011Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	115000000	USD
CY2012Q4	thc	Deferred Tax Assets Other Long Term Liabilities DeferredTaxAssetsOtherLongTermLiabilities	55000000	USD
CY2011Q4	thc	Deferred Tax Assets Other Long Term Liabilities DeferredTaxAssetsOtherLongTermLiabilities	53000000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits	214000000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits	190000000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	11000000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	31000000	USD
CY2012Q4	thc	Deferred Tax Assets Investments And Other Assets DeferredTaxAssetsInvestmentsAndOtherAssets	6000000	USD
CY2011Q4	thc	Deferred Tax Assets Investments And Other Assets DeferredTaxAssetsInvestmentsAndOtherAssets	5000000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	588000000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	695000000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	32000000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	44000000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	36000000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	41000000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1302000000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1439000000	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	550000000	USD
CY2011Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	586000000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	56000000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	61000000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1246000000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1378000000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	354000000	USD
CY2011	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	117182000	shares
CY2010	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	121080000	shares
CY2012	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	2000000	USD
CY2011	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.58
CY2012Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	342000000	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	0	USD
CY2011Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	0	USD
CY2012Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	696000000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	792000000	USD
CY2010	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1060000000	USD
CY2010Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	66000000	USD
CY2009Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	46000000	USD
CY2010Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	35000000	USD
CY2010	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	12000000	USD
CY2010	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	23000000	USD
CY2010	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1000000	USD
CY2010	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2010	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2010	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	1000000	USD
CY2011Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	35000000	USD
CY2011	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	15000000	USD
CY2011	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3000000	USD
CY2011	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2011	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	12000000	USD
CY2011	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	4000000	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	32000000	USD
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2000000	USD
CY2012	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2012	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	3000000	USD
CY2012	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2010Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	23000000	USD
CY2011	thc	Income Tax Benefit Due To Reduction Of Liabilities For Uncertain Tax Positions IncomeTaxBenefitDueToReductionOfLiabilitiesForUncertainTaxPositions	21000000	USD
CY2011	thc	Income Tax Benefit Due To Reduction Of Liabilities For Uncertain Tax Positions Continuing Operations IncomeTaxBenefitDueToReductionOfLiabilitiesForUncertainTaxPositionsContinuingOperations	2000000	USD
CY2011	thc	Income Tax Benefit Due To Reduction Of Liabilities For Uncertain Tax Positions Discontinued Operations IncomeTaxBenefitDueToReductionOfLiabilitiesForUncertainTaxPositionsDiscontinuedOperations	19000000	USD
CY2011Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	35000000	USD
CY2010	thc	Income Tax Benefit Due To Reduction Of Liabilities For Uncertain Tax Positions IncomeTaxBenefitDueToReductionOfLiabilitiesForUncertainTaxPositions	58000000	USD
CY2010	thc	Income Tax Benefit Due To Reduction Of Liabilities For Uncertain Tax Positions Continuing Operations IncomeTaxBenefitDueToReductionOfLiabilitiesForUncertainTaxPositionsContinuingOperations	45000000	USD
CY2010	thc	Income Tax Benefit Due To Reduction Of Liabilities For Uncertain Tax Positions Discontinued Operations IncomeTaxBenefitDueToReductionOfLiabilitiesForUncertainTaxPositionsDiscontinuedOperations	13000000	USD
CY2012	thc	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense To Continuing Operations UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseToContinuingOperations	1000000	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	8000000	USD
CY2012Q4	us-gaap	Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit	8000000	USD
CY2012	thc	Operating Loss Carryforward Limitation On Use Percent Of Shareholders OperatingLossCarryforwardLimitationOnUsePercentOfShareholders	0.05	pure
CY2012	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	185000000	USD
CY2010	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	9.09
CY2012	us-gaap	Amount Of Dilutive Securities Stock Options And Restrictive Stock Units AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits	0	USD
CY2011	us-gaap	Amount Of Dilutive Securities Stock Options And Restrictive Stock Units AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits	0	USD
CY2010	us-gaap	Amount Of Dilutive Securities Stock Options And Restrictive Stock Units AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits	24000000	USD
CY2012	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	4726000	shares
CY2011	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	4113000	shares
CY2010	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	19078000	shares
CY2012	thc	Effect Of Dilutive Stock Options Restricted Stock Units And Mandatory Convertible Preferred Stock Per Share Amount EffectOfDilutiveStockOptionsRestrictedStockUnitsAndMandatoryConvertiblePreferredStockPerShareAmount	-0.07
CY2011	thc	Effect Of Dilutive Stock Options Restricted Stock Units And Mandatory Convertible Preferred Stock Per Share Amount EffectOfDilutiveStockOptionsRestrictedStockUnitsAndMandatoryConvertiblePreferredStockPerShareAmount	-0.02
CY2010	thc	Effect Of Dilutive Stock Options Restricted Stock Units And Mandatory Convertible Preferred Stock Per Share Amount EffectOfDilutiveStockOptionsRestrictedStockUnitsAndMandatoryConvertiblePreferredStockPerShareAmount	-1.06
CY2012	thc	Capital Expenditure CapitalExpenditure	508000000	USD
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	185000000	USD
CY2011	thc	Capital Expenditure CapitalExpenditure	475000000	USD
CY2011	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	68000000	USD
CY2010	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	1125000000	USD
CY2011	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	121295000	shares
CY2010	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	140158000	shares
CY2011	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.56
CY2010	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	8.03
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2876000	shares
CY2011	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3421000	shares
CY2010	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5043000	shares
CY2011Q4	us-gaap	Long Lived Assets Held For Sale Impairment Charge LongLivedAssetsHeldForSaleImpairmentCharge	12000000	USD
CY2011Q4	thc	Estimated Fair Value Of Debt Instrument As Percentage Of Carrying Value EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue	1.049	pure
CY2012Q4	thc	Estimated Fair Value Of Debt Instrument As Percentage Of Carrying Value EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue	1.082	pure
CY2012Q4	thc	Preferred Stock And Other Securities Held By Captive Insurance Subsidiaries PreferredStockAndOtherSecuritiesHeldByCaptiveInsuranceSubsidiaries	1000000	USD
CY2012	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	6000000	USD
CY2011	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	4000000	USD
CY2012	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2012	thc	Number Of Hospitals Owned By Subsidiaries NumberOfHospitalsOwnedBySubsidiaries	49	item
CY2012	thc	Number Of Licensed Beds In Hospitals Operated By The Subsidiaries NumberOfLicensedBedsInHospitalsOperatedByTheSubsidiaries	13216	item
CY2012	thc	Number Of Free Standing And Provider Based Diagnostic Imaging Centers And Ambulatory Surgery Centers Operated By Subsidiaries Excluding Classified In Discontinued Operations NumberOfFreeStandingAndProviderBasedDiagnosticImagingCentersAndAmbulatorySurgeryCentersOperatedBySubsidiariesExcludingClassifiedInDiscontinuedOperations	117	item
CY2012	thc	Number Of Hospitals To Which Segment Of The Entity Provides Revenue Cycle Services NumberOfHospitalsToWhichSegmentOfTheEntityProvidesRevenueCycleServices	600	item
CY2010	thc	Capital Expenditure CapitalExpenditure	476000000	USD
CY2012	us-gaap	Revenues From Transactions With Other Operating Segments Of Same Entity RevenuesFromTransactionsWithOtherOperatingSegmentsOfSameEntity	-371000000	USD
CY2011	us-gaap	Revenues From Transactions With Other Operating Segments Of Same Entity RevenuesFromTransactionsWithOtherOperatingSegmentsOfSameEntity	-261000000	USD
CY2010	us-gaap	Revenues From Transactions With Other Operating Segments Of Same Entity RevenuesFromTransactionsWithOtherOperatingSegmentsOfSameEntity	-206000000	USD
CY2012	thc	Adjusted Earnings Before Interest Tax Depreciation And Amortization AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization	1203000000	USD
CY2011	thc	Adjusted Earnings Before Interest Tax Depreciation And Amortization AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization	1126000000	USD
CY2010	thc	Adjusted Earnings Before Interest Tax Depreciation And Amortization AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization	1036000000	USD
CY2012	us-gaap	Depreciation And Amortization DepreciationAndAmortization	430000000	USD
CY2012	us-gaap	Interest Expense InterestExpense	412000000	USD
CY2012	us-gaap	Asset Impairment Charges AssetImpairmentCharges	19000000	USD
CY2011	us-gaap	Asset Impairment Charges AssetImpairmentCharges	20000000	USD
CY2010	us-gaap	Asset Impairment Charges AssetImpairmentCharges	10000000	USD
CY2012	us-gaap	Gain Loss On Investments GainLossOnInvestments	1000000	USD
CY2012Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	106000000	USD
CY2011	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	0	USD
CY2012Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	95000000	USD
CY2011	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeBeforeTax	0	USD
CY2012Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	79000000	USD
CY2012Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	71000000	USD
CY2011	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	USD
CY2011	thc	Construction Of New And Replacement Hospitals ConstructionOfNewAndReplacementHospitals	0	USD
CY2011	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	USD
CY2011	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2010	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	0	USD
CY2012Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	57000000	USD
CY2012Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	242000000	USD
CY2012	thc	Stock Repurchase Program Expiration Date StockRepurchaseProgramExpirationDate	09-May-12
CY2012Q4	thc	Stockholders Equity Reverse Stock Split Conversion Ratio StockholdersEquityReverseStockSplitConversionRatio	0.25	shares
CY2012	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	1000000	USD
CY2012Q2	us-gaap	Payments For Repurchase Of Preferred Stock And Preference Stock PaymentsForRepurchaseOfPreferredStockAndPreferenceStock	289000000	USD
CY2010	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	USD
CY2010	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2010	thc	Proceeds From Interest Rate Swap Agreement ProceedsFromInterestRateSwapAgreement	0	USD
CY2012	thc	Allowance For Doubtful Accounts Lookback Period Used As Basis For Estimate AllowanceForDoubtfulAccountsLookbackPeriodUsedAsBasisForEstimate	P18M
CY2012	thc	Adjusted Earnings Before Income Tax AdjustedEarningsBeforeIncomeTax	334000000	USD
CY2011	thc	Adjusted Earnings Before Income Tax AdjustedEarningsBeforeIncomeTax	164000000	USD
CY2010	thc	Adjusted Earnings Before Income Tax AdjustedEarningsBeforeIncomeTax	158000000	USD
CY2010	thc	Discontinued Operation Restructuring Settlement And Impairment Provisions Before Income Tax DiscontinuedOperationRestructuringSettlementAndImpairmentProvisionsBeforeIncomeTax	1000000	USD
CY2012	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	0	USD
CY2012	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeBeforeTax	0	USD
CY2010	thc	Electronic Health Record Incentives ElectronicHealthRecordIncentives	0	USD
CY2010	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.15
CY2010	thc	Litigation And Investigation Costs LitigationAndInvestigationCosts	0	USD
CY2010	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	0	USD
CY2010	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	9.24
CY2011	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	0	USD
CY2012	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-101000000	USD
CY2012Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	4289192	shares
CY2012	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P4Y1M6D
CY2012Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	30.49
CY2012Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	3815870	shares
CY2012Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	31.47
CY2012	thc	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Percentage ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage	1.000	pure
CY2011Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7736000000	USD
CY2012Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	650000000	USD
CY2012	thc	Period For Use Of Ehr Technology To Become Eligible For Annual Medicare Incentive Payments PeriodForUseOfEHRTechnologyToBecomeEligibleForAnnualMedicareIncentivePayments	P4Y
CY2012	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-35000000	USD
CY2012	thc	Payments To Acquire Property Plant And Equipment For Continuing Operations PaymentsToAcquirePropertyPlantAndEquipmentForContinuingOperations	506000000	USD
CY2012	thc	Construction Of New And Replacement Hospitals ConstructionOfNewAndReplacementHospitals	0	USD
CY2012	thc	Payments To Acquire Property Plant And Equipment For Discontinued Operations PaymentsToAcquirePropertyPlantAndEquipmentForDiscontinuedOperations	2000000	USD
CY2012Q4	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	100000000	USD
CY2012Q4	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	3406324	shares
CY2011	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2010	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2012	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4000000	USD
CY2011Q2	thc	Stock Repurchase Program Additional Authorized Amount StockRepurchaseProgramAdditionalAuthorizedAmount	400000000	USD
CY2011	thc	Number Of Business Lines NumberOfBusinessLines	1	segment
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	722000000	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	415000000	USD
CY2012	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	2147000000	USD
CY2012	thc	Electronic Health Record Incentives ElectronicHealthRecordIncentives	-40000000	USD
CY2012	thc	Number Of Free Standing And Provider Based Out Patient Centers Operated By Subsidiaries NumberOfFreeStandingAndProviderBasedOutPatientCentersOperatedBySubsidiaries	117	item
CY2012Q4	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	64000000	USD
CY2012Q4	us-gaap	Interest Payable Current InterestPayableCurrent	125000000	USD
CY2012Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	8000000	USD
CY2012Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	335000000	USD
CY2012Q4	us-gaap	Self Insurance Reserve Noncurrent SelfInsuranceReserveNoncurrent	292000000	USD
CY2012Q4	us-gaap	Litigation Reserve Noncurrent LitigationReserveNoncurrent	2000000	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	595000000	USD
CY2012Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	16000000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	7000000	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4471000000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1288000000	USD
CY2012Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1979000000	USD
CY2012Q4	us-gaap	Minority Interest MinorityInterest	75000000	USD
CY2012	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	785000000	USD
CY2012	us-gaap	Labor And Related Expense LaborAndRelatedExpense	4257000000	USD
CY2012	us-gaap	Health Care Organization Medical Supplies And Drugs Expense HealthCareOrganizationMedicalSuppliesAndDrugsExpense	1552000000	USD
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	334000000	USD
CY2012	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax	-2000000	USD
CY2012	thc	Discontinued Operation Restructuring Settlement And Impairment Provisions Before Income Tax DiscontinuedOperationRestructuringSettlementAndImpairmentProvisionsBeforeIncomeTax	100000000	USD
CY2012	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	-25000000	USD
CY2012	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-76000000	USD
CY2011	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.08
CY2011	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.48
CY2010	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.13
CY2010	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	8.16
CY2012	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax	25000000	USD
CY2012	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-9000000	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-19000000	USD
CY2012	us-gaap	Minority Interest Increase From Stock Issuance MinorityInterestIncreaseFromStockIssuance	3000000	USD
CY2012	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	92000000	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	32000000	USD
CY2012	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	USD
CY2012	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	22000000	USD
CY2012	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	12000000	USD
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	868000000	USD
CY2012	thc	Increase Decrease In Inventories And Other Assets Current IncreaseDecreaseInInventoriesAndOtherAssetsCurrent	59000000	USD
CY2012	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	5000000	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	9000000	USD
CY2012	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	3000000	USD
CY2012	thc	Payments For Restructuring And Litigation Costs PaymentsForRestructuringAndLitigationCosts	63000000	USD
CY2012	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	211000000	USD
CY2012	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	45000000	USD
CY2012	thc	Proceeds From Sale Of Marketable Securities Long Term Investments And Other Assets ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets	17000000	USD
CY2012	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2012	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	5000000	USD
CY2012	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	1773000000	USD
CY2012	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	1693000000	USD
CY2012	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	248000000	USD
CY2012	thc	Income Tax Expense Due To Increase In Liabilities For Uncertain Tax Positions IncomeTaxExpenseDueToIncreaseInLiabilitiesForUncertainTaxPositions	3000000	USD
CY2012	us-gaap	Interest Paid Net InterestPaidNet	-376000000	USD
CY2012	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-13000000	USD
CY2011	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	11000000	USD
CY2010	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	10000000	USD
CY2010	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest	-1000000	USD
CY2012	us-gaap	Proceeds From Issuance Of Long Term Debt And Capital Securities Net ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet	1092000000	USD
CY2012	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	17000000	USD
CY2012	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	126000000	USD
CY2012	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	14000000	USD
CY2012	thc	Increase In Revenue Due To Adjustments For Prior Year Cost Reports And Related Valuation Allowances Related To Industry Wide Medicare Rural Floor Budget Neutrality Adjustment Settlement IncreaseInRevenueDueToAdjustmentsForPriorYearCostReportsAndRelatedValuationAllowancesRelatedToIndustryWideMedicareRuralFloorBudgetNeutralityAdjustmentSettlement	81000000	USD
CY2012	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest	-32000000	USD
CY2012	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	15000000	USD
CY2012	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	20000000	USD
CY2012	thc	Proceeds From Interest Rate Swap Agreement ProceedsFromInterestRateSwapAgreement	0	USD
CY2011	thc	Adjusted Supplemental Earnings Before Interest Tax Depreciation And Amortization AdjustedSupplementalEarningsBeforeInterestTaxDepreciationAndAmortization	1126000000	USD
CY2010	thc	Adjusted Supplemental Earnings Before Interest Tax Depreciation And Amortization AdjustedSupplementalEarningsBeforeInterestTaxDepreciationAndAmortization	1036000000	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	32000000	USD
CY2012	thc	Income Tax Benefit Due To Reduction Of Liabilities For Uncertain Tax Positions Continuing Operations IncomeTaxBenefitDueToReductionOfLiabilitiesForUncertainTaxPositionsContinuingOperations	3000000	USD
CY2012	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	13000000	USD
CY2012	thc	Adjusted Supplemental Earnings Before Interest Tax Depreciation And Amortization AdjustedSupplementalEarningsBeforeInterestTaxDepreciationAndAmortization	1203000000	USD
CY2011	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest	1000000	USD
CY2013Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	104285643	shares
CY2012Q4	us-gaap	Inventory Net InventoryNet	153000000	USD
CY2012Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	7000000	USD
CY2012Q4	us-gaap	Assets Held For Sale Current AssetsHeldForSaleCurrent	0	USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2012	thc	Litigation And Investigation Costs LitigationAndInvestigationCosts	0	USD
CY2012	us-gaap	Payments For Repurchase Of Convertible Preferred Stock PaymentsForRepurchaseOfConvertiblePreferredStock	292000000	USD
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	251000000	USD
CY2011	us-gaap	Payments For Repurchase Of Convertible Preferred Stock PaymentsForRepurchaseOfConvertiblePreferredStock	0	USD
CY2010	us-gaap	Payments For Repurchase Of Convertible Preferred Stock PaymentsForRepurchaseOfConvertiblePreferredStock	0	USD
CY2012	thc	Preferred Stock Repurchased During Period Value PreferredStockRepurchasedDuringPeriodValue	289000000	USD
CY2012	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2011	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	2000000	USD
CY2012	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.015	pure
CY2011	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.015	pure
CY2010	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.015	pure
CY2010Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	-268000000	USD
CY2011	us-gaap	Stockholders Equity Period Increase Decrease StockholdersEquityPeriodIncreaseDecrease	-327000000	USD
CY2012Q4	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	29.36
CY2011	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	23000000	USD
CY2012Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	46300	shares
CY2010Q4	us-gaap	Assets Assets	8500000000	USD
CY2012	thc	Maximum Number Of Hospital To Which Business Process Solution Is Provided By Subsidiaries MaximumNumberOfHospitalToWhichBusinessProcessSolutionIsProvidedBySubsidiaries	600	item
CY2012Q4	us-gaap	Goodwill Goodwill	916000000	USD
CY2011Q4	us-gaap	Goodwill Goodwill	736000000	USD

Files In Submission

Name	View Source	Status
0001104659-13-014113-index-headers.html	Edgar Link	pending
0001104659-13-014113-index.html	Edgar Link	pending
0001104659-13-014113.txt	Edgar Link	pending
0001104659-13-014113-xbrl.zip	Edgar Link	pending
a12-28129_110k.htm	Edgar Link	pending
a12-28129_1ex10dm.htm	Edgar Link	pending
a12-28129_1ex10dp.htm	Edgar Link	pending
a12-28129_1ex21.htm	Edgar Link	pending
a12-28129_1ex23.htm	Edgar Link	pending
a12-28129_1ex31da.htm	Edgar Link	pending
a12-28129_1ex31db.htm	Edgar Link	pending
a12-28129_1ex32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
g281291ba07i001.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
thc-20121231.xml	Edgar Link	completed
thc-20121231.xsd	Edgar Link	pending
thc-20121231_cal.xml	Edgar Link	unprocessable
thc-20121231_def.xml	Edgar Link	unprocessable
thc-20121231_lab.xml	Edgar Link	unprocessable
thc-20121231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$THC
TENET HEALTHCARE CORP Stock $thc

2012 Q4 Form 10-K Financial Statement

#000110465913014113 Filed on February 26, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$THC TENET HEALTHCARE CORP Stock $thc

2012 Q4 Form 10-K Financial Statement

#000110465913014113 Filed on February 26, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$THC
TENET HEALTHCARE CORP Stock $thc